TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01011790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Rhythms™ Meditation Program
Description: The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
Study: NCT03157102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher \& Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 \>92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). .

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Oxygen Treatment
Description: Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion.
Study: NCT02359253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive stretching
Description: Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive stretching
Description: Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive movement
Description: Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
Study: NCT00452218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200 mg daily and dose escalated to a maximum of 400 mg twice daily
Study: NCT03816449

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercises
Description: Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks.
Study: NCT02359253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive movement
Description: Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
Study: NCT02575456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control
Study: NCT03103711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Intervention
Description: Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments.
Study: NCT02504775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mejoral® 500 Tablets
Description: 500 mg tablet of paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mejoral® 500 Tablets
Description: 500 mg tablet of paracetamol
Study: NCT01375309

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium bifidum supplementation
Description: Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo contains dextrin
Description: 0.5 of dextrin
Study: NCT01828294

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous immunoglobulins
Description: Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
Study: NCT01208194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: solution, 60 mg, twice a week, until progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution, 60 mg, twice a week, until progression
Study: NCT03892343

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
Study: NCT01120028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: 20 mg intravenously, two doses 96 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: 20 mg intravenously, two doses 96 hours apart
Study: NCT02504775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol® Caplets
Description: 500 mg tablet of paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol® Caplets
Description: 500 mg tablet of paracetamol
Study: NCT02182453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 - single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02359253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IntelliArm
Description: During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IntelliArm
Description: During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand robot
Description: During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand robot
Description: During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
Study: NCT03662893

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioural therapy with written checklist form to complete
Description: Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioural therapy with written checklist form to complete
Description: Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimuscarinic drugs used in overactive bladder
Description: Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimuscarinic drugs used in overactive bladder
Description: Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: behavioural therapy with written guideline
Description: behavioural therapy with written guideline,which are the same as those in the checklist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioural therapy with written guideline
Description: behavioural therapy with written guideline,which are the same as those in the checklist
Study: NCT00159510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue & nitric oxide
Description: See the dosage in the previous arms
Study: NCT00885495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir, ritonavir, rosuvastatin
Description: darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin, darunavir, ritonavir
Description: rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
Study: NCT02838004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL MINI WELL READY
Description: IOL MINI WELL READY
Study: NCT03513198

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound (including fine needle aspiration)
Description: EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~* Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~* Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~* EUS-FNA will be performed in all pancreatic masses with at least four passes.

Intervention type: OTHER
Intervention: Contrast-enhanced endoscopic ultrasound (CE-EUS)
Description: CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~* The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~* The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~* All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box

Intervention type: OTHER
Intervention: Endoscopic ultrasound elastography (EG-EUS)
Description: EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~* The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~* The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~* SR and SH will be measured; with three measurements made and recorded on the embedded HDD.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced computed tomography (CT)
Description: * Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~* A template will be used to report the imaging results.~* The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~* Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).
Study: NCT02475044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: 16 Sessions of CBT.
Study: NCT03862443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Incentive
Description: The Fixed Incentive intervention is a fixed reward, in which participants are eligible for fixed weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drawing Incentive
Description: The Drawing Incentive intervention is a drawing reward, in which participants are eligible for weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
Study: NCT03577145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato, onion & lovage soup with inulin
Description: Source of polyphenols and non digestible carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato, onion & lovage soup
Description: Source of polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Source of non digestible carbohydrate
Study: NCT03318601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: Blood taking in 2 times :~* J0 : 15 mL~* J14 : 5 mL 20 mL in total volume
Study: NCT02328599

Intervention type: PROCEDURE
Intervention: Bariatric surgery involving Roux-en-Y gastric bypass
Description: Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.

Intervention type: PROCEDURE
Intervention: Bariatric surgery involving Laparoscopic adjustable gastric banding
Description: Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.

Intervention type: PROCEDURE
Intervention: Bariatric surgery involving Laparoscopic sleeve gastrectomy
Description: Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
Study: NCT02167204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FLT PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo 18F-FLT PET/CT
Study: NCT00274794

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: 10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: 10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: 375 mg/m2, IV, Once per week for 3 weeks.
Study: NCT02167204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FLT PET/CT
Study: NCT03074305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI for in-bioresorbable scaffold stenosis
Description: In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI for in-bioresorbable scaffold stenosis
Description: In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy
Study: NCT02844504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise Training 1
Description: Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise Training 2
Description: Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
Study: NCT01125644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPK-843
Description: SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
Study: NCT03387579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid 20% Lipid Emulsion for Injection
Description: Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
Study: NCT01009775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study: NCT03387579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
Study: NCT04514276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consecutive fetoneonatal healthcare pathway
Description: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
Study: NCT01691443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure sensor and wrist shaker, not marked CE, developped by Texisense
Study: NCT00185367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: 7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH D 593 B (Miranova)
Description: 7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
Study: NCT03358212

Intervention type: DRUG
Intervention: Denosumab
Description: Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment